SCHEMBL18969540

SCHEMBL18969540

COC(=O)c1ccc(CC(=O)OC(C)(C)C)cn1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.50
PARP1 P09874 1/20 0.44
P4HTM Q9NXG6 1/20 0.43
MTNR1A P48039 1/20 0.41
MTNR1B P49286 1/20 0.41
KDM4E B2RXH2 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
RIPK1 Q13546 1/20 0.40
RIPK3 Q9Y572 1/20 0.40
GPR119 Q8TDV5 1/20 0.40
NPC1 O15118 1/20 0.39
ALDH1A1 P00352 1/20 0.39
RAB9A P51151 1/20 0.39
ATR Q13535 1/20 0.39
CCNB2 O95067 1/20 0.37
CCNE2 O96020 1/20 0.37
CDK1 P06493 1/20 0.37
CDK4 P11802 1/20 0.37
CCNB1 P14635 1/20 0.37
CCND1 P24385 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9313967 0.86 MAPK1 (0.57) MAPK1PARP1P4HTMKDM4EL3MBTL1
SCHEMBL31721321 0.81 L3MBTL1 (0.50) MAPK1PARP1L3MBTL1ATRDYRK1A
SCHEMBL9314024 0.80 P4HTM (0.67) MAPK1PARP1P4HTMKDM4EL3MBTL1
SCHEMBL17665727 0.79 MTNR1A (0.49) MAPK1MTNR1AMTNR1BKDM4ENPC1
SCHEMBL23398049 0.79 MAPK1 (0.56) MAPK1PARP1P4HTMKDM4EL3MBTL1
SCHEMBL18940463 0.79 MAPK1 (0.49) MAPK1PARP1P4HTMKDM4EL3MBTL1
SCHEMBL7883731 0.78 MAPK1 (0.62) MAPK1PARP1P4HTMKDM4EL3MBTL1
SCHEMBL22031776 0.78 MAPK1 (0.48) MAPK1P4HTMKDM4EL3MBTL1GPR119
SCHEMBL23540542 0.78 GABRP (0.58) MTNR1AMTNR1BKDM4ERIPK1RIPK3
SCHEMBL25229193 0.78 ALDH1A1 (0.56) MTNR1AMTNR1BL3MBTL1RIPK1RIPK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9963448-B2 Bicyclic inhibitors of PAD4 PADLOCK THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
US-9963448-B2 Bicyclic inhibitors of PAD4 PADLOCK THERAPEUTICS, INC. (US) 2018-05-08 US disclosed
US-20170166565-A1 BICYCLIC INHIBITORS OF PAD4 PADLOCK THERAPEUTICS, INC. 2017-06-15 US disclosed
US-20170166565-A1 BICYCLIC INHIBITORS OF PAD4 PADLOCK THERAPEUTICS, INC. 2017-06-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170166565-A1 BICYCLIC INHIBITORS OF PAD4 PADI4, PADI1, PADI2 MAPK1 3276/4885PARP1 207/4885P4HTM 1344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.